Efficacies of Amphotericin B (AMB) Lipid Complex, AMB Colloidal Dispersion, Liposomal AMB, and Conventional AMB in Treatment of Murine Coccidioidomycosis

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2004 May 25

PMID 15155212

Citations 5

Authors

Gloria M Gonzalez

Rolando Tijerina

Laura K Najvar

Rosie Bocanegra

Michael G Rinaldi

John R Graybill

Affiliations

Soon will be listed here.

Abstract

The therapeutic efficacy of three lipid formulations of amphotericin B was compared with that of conventional amphotericin B in treatment of murine coccidioidomycosis. All treatments prolonged survival compared with the no-treatment group (P < 0.0001). Although conventional amphotericin B was more active than lipid formulations on reducing quantitative fungal load on a milligram-per-kilogram basis (P < 0.003 to 0.0002), the lipid preparations could be administered at higher doses, sterilizing liver and spleen tissues. The efficacies of the lipid preparations were similar in this murine model of coccidioidomycosis.

Citing Articles

Coccidioidomycosis: A Contemporary Review.

Crum N Infect Dis Ther. 2022; 11(2):713-742.

PMID: 35233706 PMC: 8887663. DOI: 10.1007/s40121-022-00606-y.

Nanomaterial-Based Antifungal Therapies to Combat Fungal Diseases Aspergillosis, Coccidioidomycosis, Mucormycosis, and Candidiasis.

Leon-Buitimea A, Garza-Cervantes J, Gallegos-Alvarado D, Osorio-Concepcion M, Morones-Ramirez J Pathogens. 2021; 10(10).

PMID: 34684252 PMC: 8539376. DOI: 10.3390/pathogens10101303.

The Rise of : Forces Against the Dust Devil Unleashed.

Caballero Van Dyke M, Thompson G, Galgiani J, Barker B Front Immunol. 2019; 10:2188.

PMID: 31572393 PMC: 6749157. DOI: 10.3389/fimmu.2019.02188.

Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis.

Sidhu R, Lash D, Heidari A, Natarajan P, Johnson R Antimicrob Agents Chemother. 2018; 62(7).

PMID: 29686150 PMC: 6021679. DOI: 10.1128/AAC.02293-17.

Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.

Olson J, Adler-Moore J, Jensen G, Schwartz J, Dignani M, Proffitt R Antimicrob Agents Chemother. 2007; 52(1):259-68.

PMID: 17967910 PMC: 2223902. DOI: 10.1128/AAC.00870-07.

References

Graybill J, Bocanegra R . Liposomal amphotericin B therapy of murine histoplasmosis. Antimicrob Agents Chemother. 1995; 39(8):1885-7. PMC: 162848. DOI: 10.1128/AAC.39.8.1885. View

ALBERT M, Adams K, Luther M, Sun S, Graybill J . Efficacy of AmBisome in murine coccidioidomycosis. J Med Vet Mycol. 1994; 32(6):467-71. DOI: 10.1080/02681219480000621. View

Gallis H . Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Clin Infect Dis. 1996; 22 Suppl 2:S145-7. DOI: 10.1093/clinids/22.supplement_2.s145. View

Storm G, van Etten E . Biopharmaceutical aspects of lipid formulations of amphotericin B. Eur J Clin Microbiol Infect Dis. 1997; 16(1):64-73. DOI: 10.1007/BF01575123. View

Wasan K, Lopez-Berestein G . Diversity of lipid-based polyene formulations and their behavior in biological systems. Eur J Clin Microbiol Infect Dis. 1997; 16(1):81-92. DOI: 10.1007/BF01575125. View

Mehta J . Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?. Leuk Res. 1997; 21(3):183-8. DOI: 10.1016/s0145-2126(96)00075-6. View

Clemons K, Stevens D . Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother. 1998; 42(4):899-902. PMC: 105563. DOI: 10.1128/AAC.42.4.899. View

Walsh T, Hiemenz J, Seibel N, Perfect J, Horwith G, Lee L . Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998; 26(6):1383-96. DOI: 10.1086/516353. View

Wong-Beringer A, Jacobs R, Guglielmo B . Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis. 1998; 27(3):603-18. DOI: 10.1086/514704. View

10.

Robinson R, Nahata M . A comparative review of conventional and lipid formulations of amphotericin B. J Clin Pharm Ther. 1999; 24(4):249-57. DOI: 10.1046/j.1365-2710.1999.00220.x. View

11.

Gallis H, Drew R, Pickard W . Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990; 12(2):308-29. DOI: 10.1093/clinids/12.2.308. View

12.

Galgiani J, Sun S, Clemons K, Stevens D . Activity of cilofungin against Coccidioides immitis: differential in vitro effects on mycelia and spherules correlated with in vivo studies. J Infect Dis. 1990; 162(4):944-8. DOI: 10.1093/infdis/162.4.944. View

13.

Clemons K, Stevens D . Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother. 1991; 35(9):1829-33. PMC: 245276. DOI: 10.1128/AAC.35.9.1829. View

14.

Clemons K, Stevens D . Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J Antimicrob Chemother. 1992; 30(3):353-63. DOI: 10.1093/jac/30.3.353. View

15.

Hiemenz J, Walsh T . Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis. 1996; 22 Suppl 2:S133-44. DOI: 10.1093/clinids/22.supplement_2.s133. View